CD274 and neoplasm: By comparison, the DFS rate at 6 months favored nivolumab in the corresponding patients in the overall population with tumor PD-L1 expression level of 1% or more (74.5% with nivolumab and 55.7% with placebo; HR 0.55, 98.72% CI 0.35–0.85) (20).